{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:15:27Z","timestamp":1775052927724,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1995,4,1]],"date-time":"1995-04-01T00:00:00Z","timestamp":796694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[1995,4]]},"DOI":"10.1378\/chest.107.4.1074","type":"journal-article","created":{"date-parts":[[2008,1,22]],"date-time":"2008-01-22T22:31:17Z","timestamp":1201041077000},"page":"1074-1082","source":"Crossref","is-referenced-by-count":43,"title":["Systemic and Hemodynamic Effects of Recombinant Tumor Necrosis Factor Alpha in Isolation Perfusion of the Limbs"],"prefix":"10.1016","volume":"107","author":[{"given":"Philippe","family":"Eggimann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Chiol\u00e9ro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Guy","family":"Chassot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Lienard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Gerain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdy","family":"Lejeune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1378\/chest.107.4.1074_bib1","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1172\/JCI112495","article-title":"Multiple biological activities of human recombinant interleukin-1","volume":"77","author":"Dinarello","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.107.4.1074_bib2","first-page":"280","article-title":"Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings","volume":"104","author":"Michie","year":"1988","journal-title":"Surgery"},{"key":"10.1378\/chest.107.4.1074_bib3","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM199006073222302","article-title":"Activation of coagulation after administration of tumor necrosis factor to normal subjects","volume":"322","author":"Van der Poll","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.107.4.1074_bib4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/0002-9343(80)90101-1","article-title":"Gram-negative bacteremia: III. Reassessment of etiology, epidemiology and ecology in 612 patients","volume":"68","author":"Kreger","year":"1980","journal-title":"Am J Med"},{"key":"10.1378\/chest.107.4.1074_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0002-9343(91)90069-A","article-title":"High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value and interplay with other cytokines","volume":"91","author":"Calandra","year":"1991","journal-title":"Am J Med"},{"key":"10.1378\/chest.107.4.1074_bib6","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/infdis\/163.6.1177","article-title":"The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome","volume":"163","author":"Dinarello","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1378\/chest.107.4.1074_bib7","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/0140-6736(91)91452-Z","article-title":"Septic shock: pathogenesis","volume":"338","author":"Glauser","year":"1991","journal-title":"Lancet"},{"key":"10.1378\/chest.107.4.1074_bib8","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1083\/jcb.107.4.1269","article-title":"Cachectin\/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses","volume":"107","author":"Sherry","year":"1988","journal-title":"J Cell Biol"},{"key":"10.1378\/chest.107.4.1074_bib9","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/330662a0","article-title":"Anti-cachectin\/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia","volume":"330","author":"Tracey","year":"1987","journal-title":"Nature"},{"key":"10.1378\/chest.107.4.1074_bib10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1126\/science.3895437","article-title":"Passive immunization against cachectin\/tumor necrosis factor protects mice from lethal effect of endotoxin","volume":"229","author":"Beutler","year":"1985","journal-title":"Science"},{"key":"10.1378\/chest.107.4.1074_bib11","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/0140-6736(90)91337-A","article-title":"Monoclonal antibody to TNF in severe septic shock","volume":"335","author":"Exley","year":"1990","journal-title":"Lancet"},{"key":"10.1378\/chest.107.4.1074_bib12","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/infdis\/161.6.1148","article-title":"Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa","volume":"161","author":"Opal","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1378\/chest.107.4.1074_bib13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/infdis\/162.2.421","article-title":"Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-\u03b1 in experimental gram-negative shock","volume":"162","author":"Silva","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1378\/chest.107.4.1074_bib14","first-page":"21","article-title":"The role of cytokine mediators in septic shock","volume":"23","author":"Tracey","year":"1990","journal-title":"Adv Surg"},{"key":"10.1378\/chest.107.4.1074_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/infdis\/161.1.79","article-title":"Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever","volume":"161","author":"Cannon","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1378\/chest.107.4.1074_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(87)91728-4","article-title":"Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease","volume":"1","author":"Waage","year":"1987","journal-title":"Lancet"},{"key":"10.1378\/chest.107.4.1074_bib17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00003246-198906000-00001","article-title":"Plasma tumor necrosis factor and mortality in critically ill septic patients","volume":"17","author":"Debets","year":"1989","journal-title":"Crit Care Med"},{"key":"10.1378\/chest.107.4.1074_bib18","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/infdis\/161.5.982","article-title":"Prognostic values of tumor necrosis factor\/cachectin, interleukin-1, alphainterferon and gamma-interferon in the serum of patients with septic shock","volume":"161","author":"Calandra","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1378\/chest.107.4.1074_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJM198808183190703","article-title":"Tumor necrosis factor and interleukin-1 in serum of children with severe infectious purpura","volume":"319","author":"Girardin","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.107.4.1074_bib20","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin induced serum protein that causes necrosis of tumors","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1378\/chest.107.4.1074_bib21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/BF00267953","article-title":"A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days","volume":"23","author":"Creaven","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1378\/chest.107.4.1074_bib22","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/bmj.298.6683.1290","article-title":"Intralesional tumor necrosis factor combined with interferon gamma in metastatic melanoma","volume":"298","author":"Retsas","year":"1989","journal-title":"BMJ"},{"key":"10.1378\/chest.107.4.1074_bib23","first-page":"4057","article-title":"Phase I trial of recombinant human interferon gamma and recombined tumor necrosis factor in patients with advanced gastrointestinal cancer","volume":"49","author":"Abbruzzee","year":"1989","journal-title":"Cancer Res"},{"key":"10.1378\/chest.107.4.1074_bib24","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/1097-0142(19911015)68:8<1694::AID-CNCR2820680806>3.0.CO;2-K","article-title":"A Southwest Oncology Group phase II trial of recombinant tumor necrosis factor in metastatic breast cancer","volume":"68","author":"Budd","year":"1991","journal-title":"Cancer"},{"key":"10.1378\/chest.107.4.1074_bib25","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1476-5381.1991.tb12490.x","article-title":"Sequential release of tumor necrosis factor, platelet activating factor and eicosanoids during endotoxin shock in anesthetized dogs: protective effects of indomethacin","volume":"104","author":"Mozes","year":"1991","journal-title":"Br J Pharmacol"},{"key":"10.1378\/chest.107.4.1074_bib26","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.4049\/jimmunol.136.7.2445","article-title":"Induction of the synthesis of tumor necrosis factor receptors by interferon gamma","volume":"136","author":"Ruggiero","year":"1986","journal-title":"J Immunol"},{"key":"10.1378\/chest.107.4.1074_bib27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.7326\/0003-4819-108-4-595","article-title":"Interferon-gamma, the activated macrophage, and host defense against microbial challenge","volume":"108","author":"Murray","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.107.4.1074_bib28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1992.10.1.52","article-title":"High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma","volume":"10","author":"Lienard","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.107.4.1074_bib29","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/BF02071526","article-title":"In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon gamma and melphalan in isolation perfusion","volume":"16","author":"Lienard","year":"1992","journal-title":"World J Surg"},{"key":"10.1378\/chest.107.4.1074_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/1043-4666(92)90024-L","article-title":"High serum levels of TNF-alpha after its administration for isolation perfusion of the limb","volume":"4","author":"Gerain","year":"1992","journal-title":"Cytokine"},{"key":"10.1378\/chest.107.4.1074_bib31","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0277-5379(82)90235-8","article-title":"Dosimetry in isolation perfusion of the limbs by assessments of perfused tissue volume and grading of toxic tissue reactions","volume":"18","author":"Wieberdink","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1378\/chest.107.4.1074_bib32","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/00005373-199305000-00002","article-title":"Combined ibuprofen and monoclonal antibody to tumor necrosis factor-alpha attenuate hemodynamic dysfunction and sepsis-induced acute lung injury","volume":"34","author":"Mullen","year":"1993","journal-title":"J Trauma"},{"key":"10.1378\/chest.107.4.1074_bib33","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM197008272830902","article-title":"Catheterisation of the heart in man with the use of a flow directed tipped catheter","volume":"283","author":"Swan","year":"1970","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.107.4.1074_bib34","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/0002-8703(72)90429-2","article-title":"Thermodilution cardiac output determination with a single flow-directed catheter","volume":"83","author":"Forrester","year":"1972","journal-title":"Am Heart J"},{"key":"10.1378\/chest.107.4.1074_bib35","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","article-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis","volume":"101","year":"1992","journal-title":"Chest"},{"key":"10.1378\/chest.107.4.1074_bib36","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/00003246-198811000-00007","article-title":"Tissue oxygen debt as a determinant of lethal and nonlethal postoperative organ failure","volume":"16","author":"Shoemaker","year":"1988","journal-title":"Crit Care Med"},{"key":"10.1378\/chest.107.4.1074_bib37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1378\/chest.102.1.216","article-title":"Elevation of cardiac output and oxygen delivery improves outcomes in septic shock","volume":"102","author":"Tuchschmidt","year":"1992","journal-title":"Chest"},{"key":"10.1378\/chest.107.4.1074_bib38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0022-1759(86)90322-4","article-title":"A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor\/tumor necrosis factor from human monocytes","volume":"95","author":"Espevik","year":"1986","journal-title":"J Immunol Methods"},{"key":"10.1378\/chest.107.4.1074_bib39","unstructured":"Fraker DL, Alexander HR. The use of tumor necrosis factor in isolated limb perfusion for melanoma and sarcoma. In: Rosenberg SA, ed. Principles and practice of oncology updates. Volume 7. Philadelphia: JB Lippincott, 1993; 5:1\u201310"},{"key":"10.1378\/chest.107.4.1074_bib40","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM199305203282008","article-title":"Pathogenetic mechanisms of septic shock","volume":"328","author":"Parillo","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.107.4.1074_bib41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.7326\/0003-4819-113-3-227","article-title":"Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy","volume":"113","author":"Parillo","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.107.4.1074_bib42","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0891-5520(20)30757-1","article-title":"Cardiovascular management of septic shock","volume":"5","author":"Vincent","year":"1991","journal-title":"Infect Dis Clin North Am"},{"key":"10.1378\/chest.107.4.1074_bib43","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/00003246-198710000-00006","article-title":"Serial cardiovascular variables in survivors and nonsurvivors in human septic shock: heart rate as an early predictor of prognosis","volume":"15","author":"Parker","year":"1987","journal-title":"Crit Care Med"},{"key":"10.1378\/chest.107.4.1074_bib44","first-page":"147","article-title":"Soft tissue sarcomas: behavior and management","volume":"16","author":"Krementz","year":"1983","journal-title":"Adv Surg"},{"key":"10.1378\/chest.107.4.1074_bib45","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/1097-0142(19860201)57:3<416::AID-CNCR2820570304>3.0.CO;2-M","article-title":"Regional perfusion: current sophistication, what next","volume":"57","author":"Krementz","year":"1986","journal-title":"Cancer"},{"key":"10.1378\/chest.107.4.1074_bib46","series-title":"Cutaneous melanoma: status of knowledge and future perspective","first-page":"581","article-title":"Regional perfusion for melanoma of the limbs: prospects for cooperative studies in north america","author":"Krementz","year":"1987"},{"key":"10.1378\/chest.107.4.1074_bib47","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0008-8749(80)90041-6","article-title":"Purified human immune gamma-interferon has more potent anticellular activity than fibroblast or leukocyte interferon","volume":"49","author":"Balok","year":"1980","journal-title":"Cell Immunol"},{"key":"10.1378\/chest.107.4.1074_bib48","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1073\/pnas.77.10.5928","article-title":"Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents","volume":"77","author":"Rubin","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1378\/chest.107.4.1074_bib49","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ijc.2910400419","article-title":"Anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) on colon cancer is in rats promoted by rat recombinant gamma-interferon","volume":"40","author":"Marquet","year":"1987","journal-title":"Int J Cancer"},{"key":"10.1378\/chest.107.4.1074_bib50","first-page":"2809","article-title":"Synergistic antitumor effects of tumor necrosis factor and gamma-interferon on human colon carcinoma cell lines","volume":"47","author":"Schiller","year":"1987","journal-title":"Cancer Res"},{"key":"10.1378\/chest.107.4.1074_bib51","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.1987.5.5.790","article-title":"A phase I clinical trial of recombinant DNA gamma-interferon","volume":"5","author":"Brown","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.107.4.1074_bib52","first-page":"4057","article-title":"Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer","volume":"49","author":"Abbruzzese","year":"1989","journal-title":"Cancer Res"},{"key":"10.1378\/chest.107.4.1074_bib53","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1989.7.10.1545","article-title":"A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo","volume":"10","author":"Demetri","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.107.4.1074_bib54","first-page":"583","article-title":"Acute in vivo effects of human recombinant tumor necrosis factor","volume":"56","author":"Remick","year":"1987","journal-title":"Lab Invest"},{"key":"10.1378\/chest.107.4.1074_bib55","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJM198806093182309","article-title":"Tumor necrosis factor in humans","volume":"318","author":"Ziegler","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.107.4.1074_bib56","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1126\/science.3764421","article-title":"Shock and tissue injury induced by recombinant human cachectin","volume":"234","author":"Tracey","year":"1986","journal-title":"Science"},{"key":"10.1378\/chest.107.4.1074_bib57","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJM198806093182301","article-title":"Detection of circulating tumor necrosis factor after endotoxin administration","volume":"318","author":"Michie","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.107.4.1074_bib58","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00000658-198903000-00011","article-title":"The effect of tumor necrosis factor and their selective inhibition by ibuprofen","volume":"209","author":"Evans","year":"1989","journal-title":"Ann Surg"},{"key":"10.1378\/chest.107.4.1074_bib59","first-page":"415","article-title":"Cachectin\/tumor necrosis factor induces lethal shock and stress hormone in the dog","volume":"164","author":"Tracey","year":"1987","journal-title":"Surg Gynecol Obstet"},{"key":"10.1378\/chest.107.4.1074_bib60","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/archsurg.1989.01410120046010","article-title":"Tumor necrosis factor induce adult respiratory distress syndrome in rats","volume":"124","author":"Ferrai-Balivera","year":"1989","journal-title":"Arch Surg"},{"key":"10.1378\/chest.107.4.1074_bib61","first-page":"147","article-title":"Cytokine appearance in human endotoxemia and primate bacteremia","volume":"166","author":"Hesse","year":"1988","journal-title":"Surg Gynecol Obstet"},{"key":"10.1378\/chest.107.4.1074_bib62","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/infdis\/162.2.454","article-title":"Monoclonal antibody to endotoxin core protects mice from Escherichia coli sepsis by a mechanism independent of tumor necrosis factor and interleukin-6","volume":"162","author":"Silva","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1378\/chest.107.4.1074_bib63","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1056\/NEJM198908033210503","article-title":"The cardiovascular response of normal humans to the administration of endotoxin","volume":"321","author":"Suffredini","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.107.4.1074_bib64","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199305203282005","article-title":"Brief report: shock and multiple-organ dysfunction after self-administration of samlonella endotoxin","volume":"328","author":"Da Silva","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.107.4.1074_bib65","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0891-5520(20)30755-8","article-title":"Current understanding of the pathogenesis of gram-negative shock","volume":"5","author":"Waage","year":"1991","journal-title":"Infect Dis Clin North Am"},{"key":"10.1378\/chest.107.4.1074_bib66","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1084\/jem.169.1.333","article-title":"The complex pattern of cytokines in serum from patients with meningococcal septic shock: association between interleukin 6, interleukin 1, and fatal outcome","volume":"169","author":"Waage","year":"1989","journal-title":"J Exp Med"},{"key":"10.1378\/chest.107.4.1074_bib67","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/00003246-199206000-00025","article-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis","volume":"20","year":"1992","journal-title":"Crit Care Med"},{"key":"10.1378\/chest.107.4.1074_bib68","first-page":"31","volume":"39","year":"1990","journal-title":"MMWR"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369216332305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369216332305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T01:17:20Z","timestamp":1684199840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369216332305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,4]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1995,4]]}},"alternative-id":["S0012369216332305"],"URL":"https:\/\/doi.org\/10.1378\/chest.107.4.1074","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[1995,4]]}}}